This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Zynerba Pharmaceuticals Crescita futura

Future criteri di controllo 5/6

Si prevede che Zynerba Pharmaceuticals aumenterà gli utili e i ricavi rispettivamente del 67.2% e 72% all'anno, mentre si prevede che l'EPS crescerà del 59% all'anno.

Informazioni chiave

67.2%

Tasso di crescita degli utili

59.0%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	17.7%
Tasso di crescita dei ricavi	72.0%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	16 Aug 2023

Aggiornamenti recenti sulla crescita futura

Recent updates

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Mar 01

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 11

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Oct 06

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

Aug 10

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Jul 22

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Jul 21

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Mar 23

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Dec 02

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

May 27

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Dec 17

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 23

Zynerba Pharmaceuticals EPS beats by $0.12

Nov 09

Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback

Oct 29

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:ZYNE - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	48	-24	-34	-32	3
12/31/2024	11	-49	-58	-56	4
12/31/2023	N/A	-43	-36	-36	4
6/30/2023	N/A	-38	-32	-32	N/A
3/31/2023	N/A	-37	-31	-31	N/A
12/31/2022	N/A	-35	-23	-23	N/A
9/30/2022	N/A	-36	-25	-25	N/A
6/30/2022	N/A	-38	-26	-26	N/A
3/31/2022	N/A	-38	-25	-25	N/A
12/31/2021	N/A	-37	-34	-33	N/A
9/30/2021	N/A	-38	-33	-33	N/A
6/30/2021	N/A	-37	-35	-35	N/A
3/31/2021	N/A	-47	-39	-39	N/A
12/31/2020	N/A	-51	-42	-41	N/A
9/30/2020	N/A	-52	-42	-42	N/A
6/30/2020	N/A	-45	-41	-40	N/A
3/31/2020	N/A	-36	-37	-36	N/A
12/31/2019	N/A	-33	-35	-35	N/A
9/30/2019	0	-30	-34	-34	N/A
6/30/2019	0	-36	-30	-29	N/A
3/31/2019	0	-37	-32	-32	N/A
12/31/2018	0	-40	-33	-32	N/A
9/30/2018	N/A	-40	-33	-33	N/A
6/30/2018	N/A	-41	-30	-30	N/A
3/31/2018	N/A	-37	-29	-29	N/A
12/31/2017	N/A	-32	-26	-26	N/A
9/30/2017	N/A	-31	-25	-25	N/A
6/30/2017	N/A	-28	-27	-26	N/A
3/31/2017	N/A	-26	N/A	-23	N/A
12/31/2016	0	-23	N/A	-20	N/A
9/30/2016	0	-22	N/A	-18	N/A
6/30/2016	0	-20	N/A	-16	N/A
3/31/2016	0	-15	N/A	-13	N/A
12/31/2015	0	-13	N/A	-10	N/A
9/30/2015	0	-9	N/A	-8	N/A
6/30/2015	1	-7	N/A	-6	N/A
3/31/2015	1	-7	N/A	-5	N/A
12/31/2014	1	-6	N/A	-4	N/A
9/30/2014	1	-5	N/A	-2	N/A
12/31/2013	1	-1	N/A	0	N/A
12/31/2012	1	-1	N/A	-1	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ZYNE diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.2% ).

Guadagni vs Mercato: Si prevede che ZYNE diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede ZYNE diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ZYNE ( 72% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ZYNE ( 72% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ZYNE è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2023/10/12 22:54
Prezzo dell'azione a fine giornata	2023/10/10 00:00
Guadagni	2023/06/30
Guadagni annuali	2022/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Zynerba Pharmaceuticals, Inc. è coperta da 13 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Corey Davis	Canaccord Genuity
Elemer Piros	Cantor Fitzgerald & Co.
Oren Livnat	H.C. Wainwright & Co.

This company has been acquired

Zynerba Pharmaceuticals Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 78% to US$1.26

Price target increased by 7.9% to US$5.80

Forecast to breakeven in 2025

Price target increased by 30% to US$7.00

Price target decreased to US$5.44

Price target increased to US$8.33

Recent updates

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

Price target decreased by 78% to US$1.26

New minor risk - Profitability

Zynerba Pharmaceuticals Provides Nasdaq Compliance Update

New major risk - Financial position

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Price target increased by 7.9% to US$5.80

Forecast to breakeven in 2025

Price target increased by 30% to US$7.00

Zynerba Pharmaceuticals Gets an Additional 180 Calendar Day Period, or Until October 30, 2023 to Regain Compliance with the Bid Price Rule

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$5.44

Zynerba Pharmaceuticals Announces Update on Reconnect, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the Annual Meeting of the American College of Neuropsychopharmacology

Zynerba Pharmaceuticals, Inc. Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel(TM) in the Journal of Neurodevelopmental Disorders

Price target increased to US$8.33

Insufficient new directors

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba Pharmaceuticals Receives a Deficiency Letter from Nasdaq

Zynerba Pharmaceuticals, Inc. Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the National Organization for Rare Disorders (Nord) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome At the International Society for Autism Research Annual Meeting

Price target decreased to US$6.95

Insufficient new directors

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Price target decreased to US$6.95

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces European Commission Grants Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Announces Executive Changes

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Pomerantz LLP and The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement Against Zynerba Pharmaceuticals, Inc

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Zynerba Pharmaceuticals, Inc. Receives Guidance from the U.S. Food and Drug Administration on Confirmatory Phase 3 Trial of Zygel in Patients with Fragile X Syndrome

New 90-day high: US$5.08

New 90-day low: US$3.27

Zynerba Pharmaceuticals, Inc. Provides Regulatory Update on Zygel™ in Fragile X Syndrome

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

New 90-day high: US$3.88

Zynerba Pharmaceuticals EPS beats by $0.12

Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback

New 90-day low: US$3.23

Zynerba Pharmaceuticals, Inc. Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome

Price target raised to US$10.00

First half earnings released

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from Russell Small Cap Completeness Index

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from Russell 3000 Growth Index

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti